Literature DB >> 9763029

Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma.

A A Keshgegian1, E Johnston, A Cnaan.   

Abstract

Predicting the clinical behavior of prostate carcinoma can be difficult; one approach is to identify molecular prognostic markers. We evaluated proliferative rate (MIB-1 antibody) and expression of bcl-2, p53, and retinoblastoma (pRB) proteins, which have cell cycle-related functions, in 208 consecutive radical prostatectomy specimens. Values were correlated with histopathologic parameters (Gleason tumor score, tumor amount, capsule invasion, and involvement of surgical margins, seminal vesicles, or lymph nodes) and with recurrence-free survival (4-year median follow-up). A high MIB-1 proliferative rate was associated with all of the measured histopathologic parameters, p53 overexpression with tumor amount, and pRB expression with positive lymph nodes. pRB and p53 expression levels were not associated with differences in recurrence-free survival. A high MIB-1 proliferative rate and bcl-2 positivity were associated with increased recurrence, both considered individually, and also independently and additively when examined together and with the most predictive histopathologic factors (Gleason tumor score and seminal vesicle involvement). MIB-1 proliferative rate and bcl-2 positivity may prove to be useful markers for poor prognosis in prostate carcinoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9763029     DOI: 10.1093/ajcp/110.4.443

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  18 in total

1.  Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10.

Authors:  Li-Yan Khor; Michelle Desilvio; Rile Li; Timothy J McDonnell; M Elizabeth H Hammond; William T Sause; Miljenko V Pilepich; Paul Okunieff; Howard M Sandler; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-07-11       Impact factor: 7.038

2.  Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study.

Authors:  Joseph J Fantony; Lauren E Howard; Ilona Csizmadi; Andrew J Armstrong; Amy L Lark; Colette Galet; William J Aronson; Stephen J Freedland
Journal:  Biomark Med       Date:  2018-06-15       Impact factor: 2.851

3.  The -938A/A genotype of BCL2 gene is associated with esophageal cancer.

Authors:  Zhigang Liu; Ruifang Sun; Weidong Lü; Chengxue Dang; Yangrong Song; Cheng Wang; Xi Zhang; Le Han; Hao Cheng; Wei Gao; Jia Liu; Guangyan Lei
Journal:  Med Oncol       Date:  2011-12-21       Impact factor: 3.064

4.  Prostate cancer: serum and tissue markers.

Authors:  G J Miller; M K Brawer; W A Sakr; J B Thrasher; R Townsend
Journal:  Rev Urol       Date:  2001

Review 5.  Emerging critical role of molecular testing in diagnostic genitourinary pathology.

Authors:  George J Netto; Liang Cheng
Journal:  Arch Pathol Lab Med       Date:  2012-04       Impact factor: 5.534

6.  The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel Deaconess Medical Center (BIDMC) approach.

Authors:  B Nicolas Bloch; Robert E Lenkinski; Neil M Rofsky
Journal:  Cancer Biomark       Date:  2008       Impact factor: 4.388

7.  Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08.

Authors:  Bret Verhoven; Yan Yan; Mark Ritter; Li-Yan Khor; Elizabeth Hammond; Christopher Jones; Mahul Amin; Jean-Paul Bahary; Kenneth Zeitzer; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-03-06       Impact factor: 7.038

Review 8.  What is the molecular pathology of low-risk prostate cancer?

Authors:  Hemamali Samaratunga; Jonathan I Epstein
Journal:  World J Urol       Date:  2008-04-12       Impact factor: 4.226

Review 9.  Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer.

Authors:  John Kurhanewicz; Mark G Swanson; Sarah J Nelson; Daniel B Vigneron
Journal:  J Magn Reson Imaging       Date:  2002-10       Impact factor: 4.813

10.  The elevated expression of a mismatch repair protein is a predictor for biochemical recurrence after radical prostatectomy.

Authors:  Alixanna M Norris; Michael Gentry; Donna M Peehl; Ralph D'Agostino; Karin D Scarpinato
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.